JP2017112892A - Method for screening skin aging inhibiting material - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a new method for screening skin aging inhibiting materials using the development level of LOC100292680 as an index.SOLUTION: There is provided a method for screening skin aging inhibiting materials which comprises a step of selecting a test substance having an increased expression level of LOC100292680 which decreases with age by comparing the expression level of LOC100292680 in a cell to which no test substance is added with the expression level of LOC100292680 in a cell to which a test substance is added.SELECTED DRAWING: Figure 1

Description

  The present invention relates to a method for screening a material for inhibiting skin aging.

The cells that make up an organism age with age. Cells are responsible for biological reactions, and form and maintain tissues and organs responsible for life activities, and aging of cells also leads to aging of individuals.
Aged cells also release factors that induce senescent cell-like responses to surrounding cells, accelerating the aging of tissues and organs. For this reason, it has been suggested that when senescent cells are removed, aging of individuals and tissues can be delayed, and aging symptoms that have already occurred can be improved (see, for example, Non-Patent Document 1).

  Therefore, senescent cells are expected as anti-aging targets (see, for example, Non-Patent Document 2). However, it has been difficult to remove senescent cells non-invasively.

  On the other hand, in recent years, non-coding RNA (ncRNA), which is RNA that does not encode a protein, has been reported as a biological component that controls cell aging (see, for example, Non-Patent Document 3). Among these ncRNAs, LncRNA that is RNA having a base number of 200 nt or more is known, and it is estimated that there are about 8200 types of LncRNA (see, for example, Non-Patent Document 4). Regarding LncRNA, recently, skin is collected from young and old donors, expression levels are compared, and it has been reported that the amount of some LncRNAs changes with aging (for example, see Non-Patent Document 5). ).

  NESPAS, FLJ46906, HOTAIR LncRNA whose expression increases with aging, and SNHG5, LOC100292680, IPW LncRNA whose expression decreases with aging, are particularly useful indicators for determining the inhibitory effect of cell aging, It has been reported that a material having an effect of suppressing skin aging can be selected using LncRNA as an index (see, for example, Patent Document 1).

JP 2015-130857 A

Baker DJ. Et al., Nature. (2011), 479, 232-236 Naylor RM. Et al., Clin Pharmacol Ther. (2013) 93, 105-116 Abdelmohsen K. et al., Wiley Interdiscip Rev RNA. (2015) 6, 615-629 Cabili MN. Et al., Genes Dev. (2011), 25, 1915-1927 Chang ALS. Et al., J Invest Dermatol. (2012), 133, 394-402

  It is an object of the present invention to provide a new method for screening a skin aging inhibitor using LOC1002680 which is one of LncRNAs.

  The present inventors have conducted research on LncRNA, and found that LOC100226880, which is one of LncRNAs whose expression level decreases with aging, is a particularly useful indicator for judging the effect of suppressing cell senescence. It was thought that the material which has the effect which suppresses aging can be screened by using an increase as an index.

  INDUSTRIAL APPLICABILITY According to the present invention, a new screening method for a skin aging inhibiting material using LOC1002680 as an index can be provided.

The figure which shows that LOC100292680 is LncRNA which suppresses aging. Diagram showing that a decrease in LOC100292680 causes cellular senescence

  Hereinafter, the present invention will be described with reference to specific experiments, but it is needless to say that the present invention is not limited to specific embodiments.

<Experiment 1: Confirmation of aging mechanism inhibition effect of LOC1002680>

  A dermal fibroblast derived from an 18-year-old donor was used as a non-senescent cell, and a gene (CDKN1A) encoding p21, which is well-known as an aging mechanism, was evaluated as an indicator of the aging state. Three types of LncRNA, SNHG5, LOC100268080, and IPW, whose expression was decreased by aging but whose function was not elucidated, were compared. When the CDKN1A expression level of the cells in which the amount of SNHG5, LOC1002680, IPW was decreased showed an increase compared to the expression level of CDKN1A in the cells in which none of the SNHG5, LOC100292680, IPW was decreased, It can be judged that the LncRNA suppressed aging.

  Cells were seeded in a 24-well plate at 30,000 cells / well and cultured in DMEM medium containing 10% FBS. After the cells adhere to the plate, siRNA against SNHG5 (Qiagen SI02824766), siRNA against LOC100292680 (Qiagen SI05395502), siRNA against IPW (Qiagen SI04915547) are introduced into the cells, respectively, and the amount of each RNA is reduced. Cultured for 72 hours. At the end of the culture, total RNA was collected using RNeasy Mini Kit (Qiagen), and reverse transcription was performed using Superscript VILO DNA Synthesis Kit (Qiagen). The expression level of CDKN1A was analyzed by a quantitative real-time PCR method using CDKN1A specific primers (Forward primer; 5′-AGAGGAGGGCCATCATCA-3 ′, Reverse primer; 5′-TGGTGTCTCGGTGACAAAGT-3 ′, Invitrogen) By calculating the ratio when the expression level in the control that performed the same operation using Negative control siRNA (Qiagen 1027280) that does not affect RNA expression was 100%, and analyzing whether CDKN1A shows an increase, Cell aging was evaluated.

The evaluation results of SNHG5, LOC1002680, and IPW are shown in FIG. CDKN1A, which is a mechanism index of cell senescence, was significantly increased in cells in which LOC100292680 was decreased (FIG. 1).
Therefore, it can be determined from the results of FIG. 1 that LOC100268080 suppressed cell senescence.

<Experiment 2: Confirmation of aging state due to reduction of LOC1002680>

Similar to Experiment 1, for dermal fibroblasts with reduced LOC1002680, cell passage was repeated every week, and after 1 passage, 2 passages and 7 passages, the Detection Detection Kit. (BioVision K320-250) was used to stain Senescence-Associated Beta-Galactosidase (SA-β-Gal) positive cells, which are the aging phenotype of the cells, and the number of SA-β-Gal positive cells relative to the total number of cells. The ratio (SA-β-Gal positive cell rate) was calculated.
Using negative control siRNA (Qiagen 1027280), the dermal fibroblasts that were evaluated in the same manner without reducing the amount of LOC100226880 were used as controls, and the SA-β-Gal positive cell rate in the control was taken as 1. The relative fold ratio of SA-β-Gal positive cells in cells in which LOC100292680 was decreased was determined to evaluate the state of cell senescence.

FIG. 2 shows the result of verification based on the evaluation of the cellular senescence phenotype in cells that have been repeatedly passaged. In cells in which LOC100292680 was decreased, SA-β-Gal positive cells, which are phenotypes of cell senescence, increased after passage 1, passage 2, and passage 7.
Therefore, it became clear that the senescence phenotype observed in cells with reduced LOC100292680 is not a transient response, but the decrease in LOC100292680 causes cellular senescence.

  Evaluation of both Experiment 1 and Experiment 2 revealed that the cells senescent due to a decrease in LOC1002680 of the cells. Therefore, it can be seen that cell aging can be prevented by increasing LOC100268080.

The screening method according to the present embodiment includes a step of selecting a test substance in which the expression level of LOC100292680 in the cell to which the test substance is added is enhanced as compared with the expression level of LOC100292680 in the cell to which the test substance is not added. .
Those skilled in the art can determine whether the change in the expression level has the effect of enhancing the expression of LOC1002680 based on the results of Experiments 1 and 2 and the results of the experiment according to Experiment 1.
Specifically, in the case where the expression level of LOC1002680 increases with respect to the cells to which the test substance is not added, it can be determined that the substance has an antiaging effect in the above step.

The test substance targeted by the screening method of the present invention may be any of a pure substance, an extract derived from animals and plants, or a mixture thereof.
The extracts derived from animals and plants mean not only animal or plant-derived extracts themselves, but also generic names of extract fractions, purified fractions, extracts or fractions, and solvent-removed products of purified products. Examples of plant-derived extracts include native or grown plants, extracts using products sold as herbal medicine ingredients, and commercially available extracts.
For the extraction operation, the whole plant part can be used, and other parts such as the plant body, the above-ground part, the rhizome part, the tree trunk part, the leaf part, the stem part, the flower ear, and the flower bud can be used. It is preferable to improve the extraction efficiency by cutting. Extraction solvents include water, alcohols such as ethanol, isopropyl alcohol and butanol, polyhydric alcohols such as 1,3-butanediol and polypropylene glycol, ketones such as acetone and methyl ethyl ketone, ethers such as diethyl ether and tetrahydrofuran. 1 type or 2 types or more selected from polar solvents, such as these, can be illustrated as a suitable thing. As a specific extraction method, for example, 1 to 30 parts by mass of a solvent is added to 1 part by mass of a plant or the like used for extraction of a plant or the like. If so, there may be mentioned a method of immersing for several hours, cooling to room temperature, removing insoluble matters and / or solvents if desired, and fractionating and purifying by column chromatography or the like.

  The skin aging inhibitory material screened by the screening method of the present invention is selected from a wrinkle prevention effect, a sagging prevention effect, a reduction effect of elasticity, a reduction effect of elasticity, an effect of preventing loss of texture, and a dullness prevention effect 1 It has more than a seed effect, and has an anti-aging effect by being blended in a skin external preparation, cosmetics, quasi drugs, foods and the like as described later.

The content (blending amount) of the skin aging inhibitor is usually 0.00001% by mass or more, preferably 0.0001% by mass or more, more preferably 0.001% by mass or more, and usually 80% by mass or less, preferably Is 30% by mass or less, more preferably 10% by mass. By setting it as the said range, it can be set as the skin aging prevention composition which show | plays an anti-aging effect suitably.
Moreover, the kind of skin aging suppression material contained in the skin aging preventing composition may be not only one but also two or more kinds.

  When blending and applying a skin aging inhibiting material to cosmetics, it is possible to broadly blend the components normally used in cosmetics, and the dosage form and use are not limited at all. Hereinafter, the components that can be contained in the cosmetic when applied to the cosmetic will be described.

Examples of active ingredients include whitening ingredients, wrinkle-improving ingredients, anti-inflammatory ingredients, animal and plant extracts. In addition, you may mix | blend with the skin aging suppression raw material which concerns on the embodiment of this invention demonstrated above.
The whitening component is not particularly limited as long as it is generally used in cosmetics. For example, 4-n-butylresorcinol, ascorbic acid glucoside, 3-O-ethylascorbic acid, tranexamic acid, arbutin, 1-triphenylmethylpiperidine, 1-triphenylmethylpyrrolidine, 2- (triphenylmethyloxy) ethanol, 2- (triphenylmethylamino) ethanol, 2- (triphenylmethyloxy) ethylamine, triphenylmethylamine, triphenylmethanol, triphenylmethane and aminodiphenylmethane, N- (o-toluyl) cysteic acid, N- (m -Toluyl) cysteic acid, N- (p-toluyl) cysteic acid, N- (p-methoxybenzoyl) cysteic acid and the like. Furthermore, as other whitening components, N-benzoyl-serine, N- (p-methylbenzoyl) serine, N- (p-ethylbenzoyl) serine, N- (p-methoxybenzoyl) serine, N- (p-fluorobenzoyl) ) Serine, N- (p-trifluoromethylbenzoyl) serine, N- (2-naphthoyl) serine, N- (4-phenylbenzoyl) serine, N- (p-methylbenzoyl) serine methyl ester, N- (p -Methylbenzoyl) serine ethyl ester, N- (2-naphthoyl) serine methyl ester, N-benzoyl-O-methylserine, N- (p-methylbenzoyl) -O-methylserine, N- (p-methylbenzoyl) -O -Acetylserine, N- (2-naphthoyl) -O-methylserine and the like.
Some of these whitening components are already on the market, or they can be obtained by synthesis. For example, 3-O-ethylascorbic acid can be synthesized by a known method described in JP-A-8-134055. There are also commercially available products (“VC ethyl” manufactured by Nippon Seika Co., Ltd.), and these can be obtained and used. 1-triphenylmethylpiperidine, 1-triphenylmethylpyrrolidine, 2- (triphenylmethyloxy) ethanol, 2- (triphenylmethylamino) ethanol, 2- (triphenylmethyloxy) ethylamine, triphenylmethylamine, triphenyl Phenylmethanol, triphenylmethane, and aminodiphenylmethane are disclosed in pamphlet of WO2010-074052 as N- (o-toluyl) cysteic acid, N- (m-toluyl) cysteic acid, N- (p-toluyl) cysteic acid, N -(P-methoxybenzoyl) cysteic acid, N- (4-phenylbenzoyl) cysteic acid and N- (p-toluoyl) homocysteic acid are disclosed in WO 2011-058730, N-benzoyl-serine, N- (p -Methylbe Zoyl) serine, N- (p-ethylbenzoyl) serine, N- (p-methoxybenzoyl) serine, N- (p-fluorobenzoyl) serine, N- (p-trifluoromethylbenzoyl) serine, N- (2 -Naphthoyl) serine, N- (4-phenylbenzoyl) serine, N- (p-methylbenzoyl) serine methyl ester, N- (p-methylbenzoyl) serine ethyl ester, N- (2-naphthoyl) serine methyl ester, N-benzoyl-O-methylserine, N- (p-methylbenzoyl) -O-methylserine, N- (p-methylbenzoyl) -O-acetylserine, N- (2-naphthoyl) -O-methylserine and the like are disclosed in WO2011 / In the pamphlet of No. 074643, the synthesis method is disclosed, respectively. It can be formed.
Content of the whitening component in cosmetics is 0.0001-30 mass% normally, 0.001-10 mass% is preferable and 0.01-5 mass% is more preferable.

  The wrinkle improving component is not particularly limited as long as it is generally used in cosmetics. For example, vitamin A or a derivative thereof is retinol, retinal, retinoic acid, tretinoin, isotretinoin, retinoic acid tocopherol, retinol palmitate, retinol acetate, ursolic acid benzyl ester, ursolic acid phosphate ester, betulinic acid benzyl ester, benzylic acid A phosphate ester is mentioned. The content of the wrinkle improving component in the cosmetic is usually 0.0001 to 30% by mass, preferably 0.001 to 10% by mass, and more preferably 0.01 to 5% by mass.

The extracts derived from animals and plants are not particularly limited as long as they are generally used for pharmaceuticals, cosmetics, foods and the like. For example, akebi extract, asunalo extract, asparagus extract, avocado extract, achacha extract, almond extract, arnica extract, aronia extract, apricot extract, ginkgo biloba extract, Indian mushroom extract, fennel extract, udo extract, sorghum extract, enmiso essence extract, buckwheat Extract, ginseng extract, hypericum extract, nettle extract, orange extract, oyster extract, cuckoo extract, chamomile extract, carrot extract, kawara mugi extract, licorice extract, kiwi extract, cucumber extract, guava extract, cucumber extract, gardenia extract, kumazasa extract, clara Extract, walnut extract, grapefruit extract, black rice extract, chlorella extract, mulberry extract, caquette extract, ghetto Extract, gentian extract, black tea extract, burdock extract, rice extract, fermented rice extract, fermented rice bran extract, rice germ oil, bilberry extract, salvia extract, bonito extract, sasa extract, hawthorn extract, sacha extract, sanctuary extract, shiitake extract, Giant extract, lion extract, perilla extract, linden extract, cypress extract, peonies extract, ginger extract, ginger root extract, cedar extract, stevia extract, stevia fermented product, hawthorn extract, elderberry extract, yarrow extract, mint extract, sage Extract, mallow extract, nematode extract, assembly extract, Sakuhakuhi extract, daiou extract, soybean extract, lysam extract, thyme extract, tasty extract Popo extract, tea extract, clove extract, chimpi extract, green tea extract, red pepper extract, toki extract, citrus extract, tonin extract, dokudami extract, tomato extract, natto extract, carrot extract, garlic extract, Novara extract, hibiscus extract, bacmond extract, Lotus extract, parsley extract, birch extract, hammame extract, cypress extract, hinoki extract, loquat extract, Japanese dandelion extract, Japanese cypress extract, grape extract, grape extract, grape seed extract, loofah extract, peppermint extract, body extract, hop extract, pine extract, mizubasho Extract, Melissa Extract, Mozuku Extract, Peach Extract, Cornflower Extract, Eucalyptus Extract, Yuzu Extract, Lily Extract, Yokuinin Eki , Mugwort extract, lavender extract, green tea extract, apple extract, rooibos tea extract, litchi extract, lettuce extract, lemon extract, forsythia extract, forsythia extract, rose extract, rosemary extract, roman chamomile extract, royal jelly extract, bitumen extract, etc. Is preferable.
The content of the animal or plant-derived extract in the cosmetic is usually 0.01 to 30% by mass, preferably 0.1 to 10% by mass, and more preferably 0.3 to 3% by mass.
Content of the animal and plant extract in foodstuffs is 0.01-80 mass% normally, 0.1-50 mass% is preferable and 1-30 mass% is more preferable.

Examples of the anti-inflammatory component include clarinone, glabrizine, glycyrrhizic acid, glycyrrhetinic acid, pantothenyl alcohol, and the like, and preferably glycyrrhizic acid and its salt, glycyrrhetinic acid alkyl and its salt, and glycyrrhetic acid and its salt.
Content of the anti-inflammatory component in cosmetics is 0.01-30 mass% normally, 0.1-10 mass% is preferable and 1-5 mass% is more preferable.

Examples of the oil component include polar oil and volatile hydrocarbon oil.
Polar oils include synthetic ester oils such as isopropyl myristate, cetyl octanoate, octyldodecyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, myristyl myristate, decyl oleate, hexyldecyl dimethyloctanoate, lactic acid Cetyl, myristyl lactate, lanolin acetate, isocetyl stearate, isocetyl isostearate, cholesteryl 12-hydroxystearylate, ethylene glycol di-2-ethylhexylate, dipentaerythritol fatty acid ester, N-alkylglycol monoisostearate, neopentyl dicaprate Glycol, diisostearyl malate, glycerin di-2-heptylundecanoate, trimethylolpropane tri-2-ethylhexylate May be mentioned trimethylolpropane triisostearate, tetra-2-ethylhexyl acid pentane erythritol, tri-2-ethylhexyl acid glycerin, trimethylolpropane triisostearate.

  Furthermore, cetyl 2-ethylhexanoate, 2-ethylhexyl palmitate, glyceryl trimyristate, glyceride tri-2-heptylundecanoate, castor oil fatty acid methyl ester, oleic acid oil, cetostearyl alcohol, acetoglyceride, palmitic acid 2 -Heptylundecyl, diisobutyl adipate, N-lauroyl-L-glutamic acid-2-octyldodecyl ester, di-2-heptylundecyl adipate, ethyl laurate, di-2-ethylhexyl sebacate, 2-hexyl myristate Decyl, 2-hexyldecyl palmitate, 2-hexyldecyl adipate, diisopropyl sebacate, 2-ethylhexyl succinate, ethyl acetate, butyl acetate, amyl acetate, triethyl citrate, octyl Toki Shishi runner formate may also be mentioned.

  Natural oils include avocado oil, camellia oil, turtle oil, macadamia nut oil, corn oil, mink oil, olive oil, rapeseed oil, egg yolk oil, sesame oil, persic oil, wheat germ oil, sasanca oil, castor oil, flaxseed oil, Safflower oil, cottonseed oil, eno oil, soybean oil, peanut oil, tea seed oil, kaya oil, rice bran oil, cinnagar oil, Japanese kiri oil, jojoba oil, germ oil, triglycerin, trioctanoic acid glycerin, triisopalmitic acid glycerin Etc.

  Examples of the volatile hydrocarbon oil include isododecane and isohexadecane.

  As surfactants, fatty acid soap (sodium laurate, sodium palmitate, etc.), anionic surfactants such as potassium lauryl sulfate, alkylsulfuric triethanolamine ether, stearyltrimethylammonium chloride, benzalkonium chloride, laurylamine oxide Cationic surfactants such as, betaine surfactants (alkyl betaines, amide betaines, sulfobetaines, etc.), imidazoline amphoteric surfactants (2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy 2) Sodium salts, etc.), amphoteric surfactants such as acylmethyl taurine, sorbitan fatty acid esters (sorbitan monostearate, sorbitan sesquioleate, etc.), glycerin fatty acids (glyceryl monostearate, etc.), Propylene glycol fatty acid esters (such as propylene glycol monostearate), hydrogenated castor oil derivatives, glycerin alkyl ethers, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbite fatty acid esters (POE-sorbitol monolaurate, etc.), POE glycerol fatty acid esters (POE-glycerol monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ethers (POE2-octyldodecyl) Ethers, etc.), POE alkylphenyl ethers (POE nonylphenyl ether, etc.), Pluronic types, POE / POP alkyl ethers ( Nonionic surfactants such as POE / POP2-decyltetradecyl ether), tetronics, POE castor oil / hardened castor oil derivatives (POE castor oil, POE hardened castor oil, etc.), sucrose fatty acid esters, alkyl glucosides, etc. , Etc.

  Examples of the alcohol include ethanol, polyethylene glycol, glycerin, 1,3-butylene glycol, erythritol, sorbitol, xylitol, maltitol, propylene glycol, dipropylene glycol, diglycerin, isoprene glycol, 1,2-pentanediol, 2,4 -Hexylene glycol, 1,2-hexanediol, 1,2-octanediol and the like.

  Thickeners include guar gum, quince seed, carrageenan, galactan, gum arabic, pectin, mannan, starch, xanthan gum, curdlan, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, methylhydroxypropylcellulose, chondroitin sulfate, dermatan sulfate, glycogen, Heparan sulfate, hyaluronic acid, sodium hyaluronate, tragacanth gum, keratan sulfate, chondroitin, mucoitin sulfate, hydroxyethyl guar gum, carboxymethyl guar gum, dextran, kerato sulfate, locust bean gum, succinoglucan, caronic acid, chitin, chitosan, carboxymethyl Chitin, agar, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, al Le-modified carboxyvinyl polymers, sodium polyacrylate, polyethylene glycol, and bentonite.

  As powders, the surface may be treated, mica, talc, kaolin, synthetic mica, calcium carbonate, magnesium carbonate, silicic anhydride (silica), aluminum oxide, barium sulfate, etc. May be treated, bengara, yellow iron oxide, black iron oxide, cobalt oxide, ultramarine, bitumen, titanium oxide, zinc oxide inorganic pigments, surface may be treated, titanium mica, fish phosphorus foil, Pearl agent such as bismuth oxychloride, red 202, red 228, red 226, yellow 4, blue 404, yellow 5, red 505, red 230, red 223 which may be raked No., Orange No. 201, Red No. 213, Yellow No. 204, Yellow No. 203, Blue No. 1, Green No. 201, Purple No. 201, Red No. 204, organic dyes, polyethylene powder, polymeta Methyl acrylic acid, nylon powder, organic powders such as organopolysiloxane elastomers, and the like.

  Examples of the UV absorber include paraaminobenzoic acid UV absorbers, anthranilic acid UV absorbers, salicylic acid UV absorbers, cinnamic acid UV absorbers, benzophenone UV absorbers, sugar UV absorbers, 2- (2 UV absorbers such as' -hydroxy-5'-t-octylphenyl) benzotriazole and 4-methoxy-4'-t-butyldibenzoylmethane.

  Moreover, the dosage form in the case of applying as cosmetics can take any of the conventionally known lotion dosage forms, emulsion dosage forms, essence dosage forms, cream dosage forms, and powder-containing dosage forms.

  Moreover, the dosage form in the case of applying as a foodstuff can take all the tablets, capsules, and powders which are generally known.

  EXAMPLES Hereinafter, although an Example demonstrates this invention concretely, this invention is not limited to a following example, unless the summary is exceeded.

<Example 1: Screening of plant extracts that increase LOC1002680>

  The effect of aging fibroblasts on LOC100292680 was evaluated using a plant extract presumed to be formulated by the manufacturer in the hope of improving aging in products on the market in this technical field.

  Dermal fibroblasts from a 68-year-old Caucasian were used as senescent cells. Fibroblasts subcultured with 10% FBS-containing DMEM medium until PDL24 or higher were seeded in a 96-well plate at 7000 cells / well and cultured for 24 hours. Thereafter, the medium was replaced with a medium containing 0.5% of the plant extract and further cultured for 24 hours. Moreover, it culture | cultivated similarly in the culture medium which contains the solvent of each extract as a control 0.5%. At the end of the culture, the expression level of LOC10000292680 was analyzed by quantitative real-time PCR using FastLane Cell SYBR Green Kit (Qiagen 216213) and LOC10000292680 specific primer (Qiagen Hs_LINC00942_1_SG). The amount was determined.

Table 1 shows the results of the extract exceeding the expression level of LOC1002680 before addition of the test substance.
From Table 1, by adding extracts of 14 kinds of plants such as aloe, age, oxon, auren, raspberry, gennoshouko, birch, squirrel, camellia, spruce, butcher bloom, button, mandarin orange fruit, and yukinoshita, respectively. It was found that LOC1002680 increased by more than 10% over control.
In particular, 12 types of aloe, age, orange, orange, raspberry, squirrel, camellia, spruce, butcher bloom, buttons, mandarin orange fruit, and yukinoshita have a significant increase in LOC100292680, which is expected to improve cell aging. It was.
Among these 12 species, Mandarin orange fruit, which had the weakest effect of increasing LOC1002680, increased LOC100292680 expression by 17% and increased the average value of LOC100292680, but 13% in Genokosho, where no significant increase was observed Therefore, if an increase in LOC100226880 exceeding 13% is observed, a test substance capable of improving aging can be selected.

  Therefore, a new skin aging inhibiting material can be searched for by screening using LOC1002680 of the present invention as an index.

  INDUSTRIAL APPLICABILITY According to the present invention, a new screening method for a skin aging inhibiting material can be provided using LOC1002680 as an index.

Claims (3)

  Comparing the expression level of LOC100292680 in a cell to which the test substance is not added with the expression level of LOC100292680 in the cell to which the test substance is added, and selecting the test substance having an increased expression level. A screening method for a material for inhibiting skin aging.   A screening method for a skin aging-suppressing material, characterized in that, when the expression level of LOC100226880 exceeds 13% as compared with the case where it is not added by adding a test substance, it is judged to have an aging improving effect.   The skin aging inhibiting material has one or more effects selected from the group consisting of prevention of wrinkles, sagging, prevention of reduction of elasticity, prevention of reduction of elasticity, prevention of loss of texture, and prevention of dullness. The screening method according to claim 1 or 2.